Skip to main content
AAO-HNSF 2024 Annual Meeting & OTO EXPO Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Expert Lectures

Professional and Personal Development

Lessons learned from National Institute on Deafness and Other Communication Disorders Clinical Trials

Tuesday, October 1, 2024
11:00 AM – 12:00 PM EDT
Location: MBCC, 244-245
CME/MOC Credit: 1
Disclosure(s):
Jean S. Verheyden, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Castilla McNamara, PhD, MPA, CIP:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

PROGRAM DESCRIPTION: National Institute on Deafness and Other Communication Disorders (NIDCD) conducts and supports research and research training related to disease prevention and health promotion; addresses special biomedical and behavioral problems experienced by people who have communication impairments or disorders; supports research evaluating approaches to the identification and treatment of communication disorders and patient outcomes; and supports efforts to create devices that substitute for lost and impaired sensory and communication function.
The creation of such interdisciplinary teams—in which scientists with varied perspectives are cross-trained by one another—could spark new ways to better prevent, detect, and treat communication and chemosensory disorders by identifying new directions for scientific discovery, conducting hypothesis-driven clinical trials, assessing new diagnostic tools and interventions, and improving public health and well-being.

Learning Objectives:

  1. To provide an overview of the National Institute on Deafness and other Communication Disorders (NIDCD) mission and research areas to direct those interested in available NIDCD specific clinical trial funding opportunities.
  2. To guide investigators to available tools and references on NIH clinical trials determination for research studies.
  3. To clarify between a NIDCD R01 low risk clinical trial funding opportunity and a NIDCD U01 cooperative agreement for clinical trials funding opportunity.

    Lead Presenter(s)

  • JV

    Jean S. Verheyden, MD

    Otolaryngology Physician
    VA Southern Nevada Healthcare System
    North Las Vegas, NV, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

    • Co-Presenter(s)

  • CM

    Castilla McNamara, PhD, MPA, CIP

    Operations Officer, Clinical Trials Section
    NIH NIDCD
    Rockville, MD, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.